CRISPR Therapeutics (NASDAQ:CRSP) Earns “Neutral” Rating from Cantor Fitzgerald

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “neutral” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports.

Several other brokerages also recently issued reports on CRSP. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Truist Financial raised their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Barclays raised their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Chardan Capital decreased their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Stock Up 3.0 %

CRISPR Therapeutics stock opened at $53.80 on Wednesday. The stock has a market cap of $4.61 billion, a price-to-earnings ratio of -12.34 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The business has a 50 day moving average price of $41.89 and a two-hundred day moving average price of $45.98.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts expect that CRISPR Therapeutics will post -5.04 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after acquiring an additional 1,074,238 shares during the last quarter. Capital International Investors boosted its holdings in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after purchasing an additional 816,789 shares in the last quarter. Baker BROS. Advisors LP lifted its position in CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares during the last quarter. Finally, State Street Corp raised its position in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.